Evidence map›Paper›PMID 36981522›Full record

ArticleHealthcare (Basel, Switzerland)2023

A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID.

Lindsay S Petracek, Camille A Broussard, Renee L Swope, Peter C Rowe

Open access · goldFull text readCase Reports
In one paragraph

Article in Healthcare (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Patient-reported treatment outcomes in ME/CFS and long COVID.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Lindsay S PetracekThe Division of Adolescent and Young Adult Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine Baltimore, Baltimore, MD 21205, USA.
Camille A BroussardThe Division of Adolescent and Young Adult Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine Baltimore, Baltimore, MD 21205, USA.
Renee L SwopeThe Division of Adolescent and Young Adult Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine Baltimore, Baltimore, MD 21205, USA.
Peter C RoweThe Division of Adolescent and Young Adult Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine Baltimore, Baltimore, MD 21205, USA.ORCID 0000-0002-3586-2677
Johns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Persistent fatigue is one of the most common symptoms of post-COVID conditions, also termed long COVID. At the extreme end of the severity spectrum, some individuals with long COVID also meet the criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), raising the possibility that symptom management approaches for ME/CFS may benefit some long COVID patients. We describe the long-term outcomes of a 19-year-old male who developed profound impairment consistent with ME/CFS after a SARS-CoV-2 infection early in the pandemic. We evaluated and treated him using our clinic's approach to ME/CFS. This included a history and physical examination that ascertained joint hypermobility, pathological reflexes, physical therapy maneuvers to look for a range of motion restrictions in the limbs and spine, orthostatic testing, and screening laboratory studies. He was found to have profound postural tachycardia syndrome, several ranges of motion restrictions, and mast cell activation syndrome. He was treated according to our clinic's guidelines for managing ME/CFS, which included manual physical therapy maneuvers and both non-pharmacologic measures and medications directed at postural tachycardia syndrome and mast cell activation. He experienced significant improvement in his symptoms over 30 months. His case emphasizes how the application of the principles of treating ME/CFS has the potential to provide a direction for treating long COVID.

Indexed as

adolescentchronic fatigue syndromelong COVIDmyalgic encephalomyelitisorthostatic intolerancepost COVID-19 condition

Identifiers

PMID36981522
PMCPMC10048325
OpenAlexW4327595972

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read10
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.